Email this article 
PREVENTION AND MONITORING OF CARDIOVASCULAR COMPLICATIONS IN PATIENTS WITH LUMINAL HER2-NEGATIVE METASTATIC BREAST CANCER
- Authors: Kozyavin N.A.1, Semiglazova T.Y.1,2
-
Affiliations:
- N.N. Petrov National Medical Research Center of Onclology, Ministry of Health of Russia
- I.I. Mechnikov North-Western State Medical University Ministry of Health of Russia
- Issue: Vol 14, No 2 (2018)
- Pages: 61-71
- Section: MAMMOLOGY. REVIEWS
- Published: 15.08.2018
- URL: https://ojrs.abvpress.ru/ojrs/article/view/595
- DOI: https://doi.org/10.17650/1994-4098-2018-14-2-61-71
- ID: 595
Cite item
Full Text
Abstract
Myocardial dysfunction, heart failure and prolongation of the QTc interval are dangerous cardiovascular complications associated with systemic treatment for luminal HER2-negative metastatic breast cancer. Special monitoring is required to control such complications, especially when introducing new drugs. Understanding the mechanisms underlying the development of cardiovascular complications as well as diagnostic, prevention, and treatment strategies is important for optimal patient management.
About the authors
N. A. Kozyavin
N.N. Petrov National Medical Research Center of Onclology, Ministry of Health of Russia
Author for correspondence.
Email: kozjavin-nikita@mail.ru
ORCID iD: 0000-0003-2759-4817
68 Leningradskaya St., Pesochnyi Settlement, Saint Petersburg 197758 Russian Federation
T. Yu. Semiglazova
N.N. Petrov National Medical Research Center of Onclology, Ministry of Health of Russia;I.I. Mechnikov North-Western State Medical University Ministry of Health of Russia
Email: tsemiglazova@mail.ru
ORCID iD: 0000-0002-4305-6691
68 Leningradskaya St., Pesochnyi Settlement, Saint Petersburg 197758
41 Kirochnaya St., Saint Petersburg 191015
Russian FederationReferences
Supplementary files
